In Pennsylvania, researchers are using genomic profiling to help future treatment of pancreatic cancer, which is the third leading cause of cancer deaths in the United States and has a low survival rate of 8%. One study found a mutation in the anaplastic lymphoma kinase gene and used targeted therapy for the mutated gene. Another study used existing medicines to improve pancreatic cancer outcomes with similar genetic mutations. The key was using the targeted genetic therapy early on as they found patients who had advanced too far with pancreatic cancer did not benefit as much as patients who were in the earlier stages.
Latest article
Mercedes-Benz taps Modern Meadow for 80% plant-based leather
In Germany, luxury car manufacturer Mercedes-Benz has partnered with New Jersey biodesign firm Moden Meadow to develop a next-generation leather alternative for its CONCEPT...
Bioluminescent dress from van Herpen portends era of living couture
In France, Dutch fashion designer Iris van Herpen has unveiled a dress embedded with 125 million bioluminescent algae at Paris Haute Couture Week 2025....
Stella McCartney’s latest sneaker can be composted, smells of cinnamon
In London, sustainable fashion pioneer Stella McCartney has unveiled a new version of its S-Wave sneakers, featuring soles made entirely from BioCir Flex, a...